GSA Capital Partners LLP decreased its holdings in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 62.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,134 shares of the specialty pharmaceutical company’s stock after selling 67,600 shares during the period. GSA Capital Partners LLP owned about 0.08% of Supernus Pharmaceuticals worth $1,645,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Algert Global LLC raised its stake in Supernus Pharmaceuticals by 21.1% in the third quarter. Algert Global LLC now owns 62,681 shares of the specialty pharmaceutical company’s stock worth $2,507,000 after buying an additional 10,914 shares in the last quarter. Neuberger Berman Group LLC bought a new position in Supernus Pharmaceuticals in the third quarter worth approximately $660,000. California Public Employees Retirement System raised its stake in Supernus Pharmaceuticals by 21.1% in the third quarter. California Public Employees Retirement System now owns 47,090 shares of the specialty pharmaceutical company’s stock worth $1,884,000 after buying an additional 8,190 shares in the last quarter. Bamco Inc. NY raised its stake in Supernus Pharmaceuticals by 100.9% in the third quarter. Bamco Inc. NY now owns 89,621 shares of the specialty pharmaceutical company’s stock worth $3,585,000 after buying an additional 45,019 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in Supernus Pharmaceuticals in the third quarter worth approximately $10,646,000. 98.34% of the stock is owned by institutional investors.

Supernus Pharmaceuticals Inc (SUPN) opened at $39.65 on Monday. Supernus Pharmaceuticals Inc has a 1-year low of $23.10 and a 1-year high of $50.04. The stock has a market cap of $2,032.54, a price-to-earnings ratio of 37.41, a price-to-earnings-growth ratio of 1.68 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals’s quarterly revenue was up 41.5% compared to the same quarter last year. analysts predict that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

A number of equities analysts recently commented on the stock. SunTrust Banks reissued a “buy” rating and issued a $61.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Cowen set a $50.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Janney Montgomery Scott reissued a “hold” rating and issued a $47.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. B. Riley reissued a “buy” rating and issued a $50.00 price objective on shares of Supernus Pharmaceuticals in a research note on Monday, November 20th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $49.60.

TRADEMARK VIOLATION NOTICE: “GSA Capital Partners LLP Sells 67,600 Shares of Supernus Pharmaceuticals Inc (SUPN)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/gsa-capital-partners-llp-sells-67600-shares-of-supernus-pharmaceuticals-inc-supn/1770712.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.